Literature DB >> 22012638

Comparison of the rapidity of onset of the therapeutic effect between nateglinide and mitiglinide by PK/PD analysis in rats.

Toshiyuki Takanohashi1, Harumi Arisaka, Kazuyuki Ubukata, Masahiro Hayashi, Yasuhiko Yamada.   

Abstract

Nateglinide and mitiglinide are immediate short-acting insulinotropic agents. Both are administered preprandially to control postprandial hyperglycemia. Glinide drugs are characterized by immediate onset as well as rapid disappearance of effect as compared with sulfonylurea drugs. We examined the rapidity of onset of the therapeutic effect between nateglinide and mitiglinide by pharmacokinetic/pharmacodynamic analysis using the receptor-binding-dissociation model in rats. Nateglinide or mitiglinide was administered orally or intravenously to rats and blood samples were collected at various time-points post administration. The plasma concentrations of the unbound drug forms and the blood glucose were measured. When the simultaneous fitting of oral administration and intravenous administration was performed using the receptor-binding-dissociation model, the measured values exhibited good correspondence with the fitting curve. Moreover, the time-courses of changes of the receptor-binding rate (sulfonylurea receptor) were examined using the parameters (k (on): second-order binding association constant to the receptor, Φ: receptor-binding occupancy ratio) obtained from the analysis. The results showed that the binding rate, which is important for glinide drugs in the early phase after administration, was obviously higher for nateglinide than that for mitiglinide from 10 min after oral administration and between 0 and 30 min after intravenous administration. These results suggest a more rapid onset of the therapeutic effect of nateglinide than that of mitiglinide after the drug is distributed into the blood.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22012638     DOI: 10.1007/s13318-011-0068-3

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  14 in total

Review 1.  [Effects of mitiglinide in treatment of impaired glucose tolerance].

Authors:  Hiroshi Katahira; Hitoshi Ishida
Journal:  Nihon Rinsho       Date:  2005-02

2.  Characterization of sulfonylurea receptors in isolated human pancreatic islets.

Authors:  G Giannaccini; R Lupi; M L Trincavelli; R Navalesi; L Betti; P Marchetti; A Lucacchini; S Del Guerra; C Martini
Journal:  J Cell Biochem       Date:  1998-11-01       Impact factor: 4.429

Review 3.  [A rapid- and short-acting insulinotropic agent KAD-1229].

Authors:  H Komatsu; H Ohnota; T Koizumi; F Satoh
Journal:  Nihon Rinsho       Date:  1997-11

4.  Comparative pharmacodynamics of eight calcium channel blocking agents in Japanese essential hypertensive patients.

Authors:  S Shimada; Y Nakajima; K Yamamoto; Y Sawada; T Iga
Journal:  Biol Pharm Bull       Date:  1996-03       Impact factor: 2.233

5.  In vitro-in vivo correlation of pharmacodynamics of felodipine in essential hypertensive patients based on an ion-channel binding model.

Authors:  Y Nakajima; K Yamamoto; S Shimada; H Kotaki; Y Sawada; T Iga
Journal:  Biol Pharm Bull       Date:  1996-08       Impact factor: 2.233

6.  Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide.

Authors:  T Ikenoue; K Okazaki; S Fujitani; Y Tsuchiya; M Akiyoshi; T Maki; N Kondo
Journal:  Biol Pharm Bull       Date:  1997-04       Impact factor: 2.233

7.  Effect of nateglinide on the incidence of diabetes and cardiovascular events.

Authors:  Rury R Holman; Steven M Haffner; John J McMurray; M Angelyn Bethel; Björn Holzhauer; Tsushung A Hua; Yuri Belenkov; Mitradev Boolell; John B Buse; Brendan M Buckley; Antonio R Chacra; Fu-Tien Chiang; Bernard Charbonnel; Chun-Chung Chow; Melanie J Davies; Prakash Deedwania; Peter Diem; Daniel Einhorn; Vivian Fonseca; Gregory R Fulcher; Zbigniew Gaciong; Sonia Gaztambide; Thomas Giles; Edward Horton; Hasan Ilkova; Trond Jenssen; Steven E Kahn; Henry Krum; Markku Laakso; Lawrence A Leiter; Naomi S Levitt; Viacheslav Mareev; Felipe Martinez; Chantal Masson; Theodore Mazzone; Eduardo Meaney; Richard Nesto; Changyu Pan; Rudolf Prager; Sotirios A Raptis; Guy E H M Rutten; Herbert Sandstroem; Frank Schaper; Andre Scheen; Ole Schmitz; Isaac Sinay; Vladimir Soska; Steen Stender; Gyula Tamás; Gianni Tognoni; Jaako Tuomilehto; Alberto S Villamil; Juraj Vozár; Robert M Califf
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

8.  Theory based analysis of anti-inflammatory effect of infliximab on Crohn's disease.

Authors:  Yoko Furuya; Takeshi Ozeki; Risa Takayanagi; Haruko Yokoyama; Kiyoshi Okuyama; Yasuhiko Yamada
Journal:  Drug Metab Pharmacokinet       Date:  2007-02-25       Impact factor: 3.614

9.  Pharmacokinetic/pharmacodynamic analysis of neutrophil proliferation induced by rhG-CSF in patients receiving antineoplastic drugs.

Authors:  Munetoshi Sugiura; Yoshiyuki Ohno; Yasuhiko Yamada; Hiroshi Suzuki; Tatsuji Iga
Journal:  Yakugaku Zasshi       Date:  2004-09       Impact factor: 0.302

Review 10.  Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.

Authors:  James F McLeod
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more
  1 in total

1.  Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers.

Authors:  Shijia Liu; Peidong Chen; Yang Zhao; Guoliang Dai; Bingting Sun; Yao Wang; Anwei Ding; Wenzheng Ju
Journal:  BMC Pharmacol Toxicol       Date:  2017-07-04       Impact factor: 2.483

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.